Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma Summary Autologous CD19 CAR-T cell therapy shows promise for treating relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). Studies Read More